Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA

被引:134
作者
Heysell, Scott K. [1 ]
Moore, Jane L. [2 ]
Keller, Suzanne J. [2 ]
Houpt, Eric R. [1 ]
机构
[1] Univ Virginia, Charlottesville, VA 22908 USA
[2] Virginia Dept Hlth, Richmond, VA USA
关键词
DIABETES-MELLITUS; PULMONARY TUBERCULOSIS; TREATMENT OUTCOMES; RIFAMPIN; PHARMACOKINETICS; PYRAZINAMIDE; ETHAMBUTOL; COHORT; IMPACT;
D O I
10.3201/eid1610.100374
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Therapeutic drug monitoring may be useful in tuberculosis management, but programmatic implementation is understudied. We performed a retrospective cohort study to determine prevalence of lower than expected levels of isoniazid, rifampin, ethambutol, and pyrazinamide measured at time of estimated peak serum concentration. Patients were tested for serum concentration at 2 hours after medication administration. When patients were tested, 22 had concentrations lower than expected range for rifampin, 23 of 39 patients had low levels of isoniazid, and 8 of 26 patients had low levels of ethambutol; all 20 patients tested for pyrazinamide were within expected range. Over 26 months, 42 patients met criteria for slow response. Diabetes was associated with slow response (p<0.001), and persons with diabetes were more likely than persons without diabetes to have low rifampin levels (p = 0.03). Dosage adjustment of rifampin was more likely to elevate serum concentration to the target range than adjustment of isoniazid given in daily doses (p = 0.01).
引用
收藏
页码:1546 / 1553
页数:8
相关论文
共 30 条
[1]
The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis [J].
Alisjahbana, Bachti ;
Sahiratmadja, Edhyana ;
Nelwan, Erni J. ;
Purwa, Anugrah Maya ;
Ahmad, Yana ;
Ottenhoff, Tom H. M. ;
Nelwan, Ronald H. H. ;
Parwati, Ida ;
van der Meer, Jos W. M. ;
van Crevel, Reinout .
CLINICAL INFECTIOUS DISEASES, 2007, 45 (04) :428-435
[2]
*AM THOR SOC, 2003, MMWR RECOMM REP, V52, P1203
[3]
[Anonymous], 2003, AM J RESP CRIT CARE, V167, P603
[4]
[Anonymous], 2009, GLOB TUB CONTR SHORT
[5]
Peak plasma rifampicin level in tuberculosis patients with slow culture conversion [J].
Chang, K. -C. ;
Leung, C. -C. ;
Yew, W. -W. ;
Kam, K. -M. ;
Yip, C. -W. ;
Ma, C. -H. ;
Tam, C. -M. ;
Leung, E. C. -C. ;
Law, W. -S. ;
Leung, W. -M. .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2008, 27 (06) :467-472
[6]
Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV-Infected Cohort of Adults with Tuberculosis from Botswana [J].
Chideya, Sekai ;
Winston, Carla A. ;
Peloquin, Charles A. ;
Bradford, William Z. ;
Hopewell, Philip C. ;
Wells, Charles D. ;
Reingold, Arthur L. ;
Kenyon, Thomas A. ;
Moeti, Themba L. ;
Tappero, Jordan W. .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (12) :1685-1694
[7]
Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs [J].
Davies, G. R. ;
Nuermberger, E. L. .
TUBERCULOSIS, 2008, 88 :S65-S74
[8]
Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears [J].
Diacon, A. H. ;
Patientia, R. F. ;
Venter, A. ;
van Helden, P. D. ;
Smith, P. J. ;
McIlleron, H. ;
Maritz, J. S. ;
Donald, P. R. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (08) :2994-2996
[9]
Impact of Diabetes Mellitus on Treatment Outcomes of Patients with Active Tuberculosis [J].
Dooley, Kelly E. ;
Tang, Tania ;
Golub, Jonathan E. ;
Dorman, Susan E. ;
Cronin, Wendy .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2009, 80 (04) :634-639
[10]
Diagnostic standards and classification of tuberculosis in adults and children [J].
Dunlap, NE ;
Bass, J ;
Fujiwara, P ;
Hopewell, P ;
Horsburgh, CR ;
Salfinger, M ;
Simone, PM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (04) :1376-1395